相关实验视频
Updated: Jul 17, 2025

08:53
Artificial Lung Device Priming for In Situ Fiber Bundle Surface Grafting
Published on: March 28, 2025
465
在新生儿和儿科外体膜氧化期间补充抗血素III
Noy Meshulami1, Robert Green1,2, Shubhi Kaushik1,3
1Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Artificial organs
|September 2, 2023
概括
在患有体外膜氧化 (ECMO) 的儿科和新生儿患者中,抗血素III (AT3) 补充剂增加了出血率,但没有减少血栓形成. 临床医生在考虑为ECMO患者补充AT3时应谨慎行事.
科学领域:
- 儿科重症监护医药 儿科重症监护医药
- 新生儿重症监护室新生儿重症监护室
- 通过心肺绕道术 (cardiopulmonary bypass) 进行心肺绕道.
背景情况:
- 流血和血栓形成是身体外膜氧化 (ECMO) 的主要并发症.
- 氨酸是标准的抗凝剂,但其有效性可能会随着抗血素III (AT3) 水平的降低而降低.
- 新生儿和儿科ECMO患者可能有AT3缺乏,因此需要考虑AT3补充.
研究的目的:
- 在ECMO治疗新生儿和儿科患者中研究抗血素III (AT3) 补充剂与出血和血栓形成率之间的关联.
- 评估AT3补充剂在缓解ECMO相关并发症方面的有效性.
主要方法:
- 在ECMO数据库中分析出血和血栓形成 (514名患者).
- 构建每日回归模型,以评估AT3补充剂对出血和血栓形成率的影响.
- 由于生理差异,针对儿科和新生儿患者群体进行了单独的分析.
主要成果:
- 在儿科 (aOR 1.59) 和新生儿 (aOR 1.37) 患者中,AT3的使用与明显更高的每日出血率有关.
- 在任何一组患者中,AT3补充剂都没有显示出血栓形成率的降低.
结论:
- 儿科和新生儿ECMO患者的AT3补充与出血风险增加有关.
- 在这个人群中,AT3补充似乎没有降低血栓形成率.
- 建议临床医生在考虑为ECMO患者提供外源AT3补充时谨慎行事.
相关概念视频
Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Pulmonary Embolism III: Nursing Management
15
A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
15
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
10
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
10
Anticoagulant Drugs: Low-Molecular-Weight Heparins
749
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
749
Venous Thrombosis IV: Nursing Management
14
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
14
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K

